A post-hoc analysis of the phase 3 AMAGINE-2 and AMAGINE-3 trials including 3,712 people with moderate-to-severe psoriasis showed that 90% of patients treated with brodalumab who achieved Psoriasis Area and Severity Index (PASI) score of 100 also experienced a sustained PASI-100 score .
In the same analysis, only 77% of patients treated with ustekinumab who achieved PASI-100 also experienced sustained PASI-100. The authors measured sustained PASI-100 as the time to inadequate response, based on a static physician’s global assessment (sPGA) of ≥3 or persistent values of 2 over at least a 4-week period or after week 16. Since the subpopulations of patients treated with brodalumab and ustekinumab in these studies had different baseline characteristics, the authors did not apply statistical comparisons.
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Certolizumab: Long-term safety and efficacy results for psoriasis-related nail disease Next Article
Switching infliximab biosimilars safe in treating chronic plaque psoriasis »
Table of Contents: SPIN 2019
Aetiology: Triggers and Risk Factors
Advances in Therapy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.